Patent Issues in the Development of Biosimilar Medicines

Join industry professionals at SMi's event in Central London on 21st July 2011; for further information and to register please visit the website.
By: SMi Group Ltd
 
March 14, 2011 - PRLog -- Biosimilar medicines are already a commercial reality in the European Union.  The U.S. Healthcare Reform legislation – with its defined pathway for the regulatory approval of follow-on biologics – should open up the U.S. market in the future, but in the meantime, the next batch of biosimilars will face other difficulties in reaching the market, both in the EU and elsewhere. SMi Group provides a CPD accredited masterclass which helps industry professionals to deal with patents issues during biosimilar medicine development for the EU market.

This event covers an extensive range of topics and provides a comprehensive survey and in-depth analysis of IP of biosimilars in advanced markets, specific, detailed focus on insulin analogues and pegylation, development of Monoclonal antibodies regulation and an outline of the future opportunities in developing markets and the EU. The masterclass is headed by an expert, Dr Duncan Curley (director of London-based law practice, Innovate Legal), who has in-depth knowledge and experience of IP law practice; where he has worked on many high-profile cases e.g. Lenzing v Courtaulds (fibre technology), Bespak v 3M (metered dose inhalers for asthma) and acts for a number of multinational companies on freedom to operate, patent clearance and litigation issues.

Gaining a deeper understanding into the IP of biosimilars is crucial to the dealing with the difficulties of them reaching the market, spotting future opportunities and developing strategies to help companies in the development of biosimilar medicines for the EU market.

Benefits of attending SMi’s CPD accredited masterclass, Patent Issues in the Development of Biosimilar Medicines:
Upon completion of this Masterclass, through a combination of presentations and interactive discussion, you will:

•Analyse the IP of biosimilars in advanced markets
•Discuss patent issues that may arise during the development of biosimilar medicines for the EU market
•Debate case studies involving IP evolution, cost effectiveness and business models
•Gain knowledge about the development of Monoclonal antibodies regulation
•Learn from an extremely experienced Masterclass leader with in-depth and specific knowledge of IP legal practice in the pharmaceutical sector
•Gain valuable CPD points through attendance

For further information and the opportunity to register online please visit; http://www.smi-online.co.uk/biosimilarsclass8.asp
End
Source:SMi Group Ltd
Email:***@smi-online.co.uk Email Verified
Zip:SE1 0HS
Tags:Pharma, Intellectual, Property, Biotech, Patents, Operations, Market, Intelligence, Strategic, Partnering
Industry:Biotech, Medical, Business
Location:London, Greater - England
Account Email Address Verified     Account Phone Number Verified     Disclaimer     Report Abuse



Like PRLog?
9K2K1K
Click to Share